摘要
目的探讨阿托伐他汀可通过降低急性冠脉综合征(ACS)的C-反应蛋白(CRP)水平而发挥抗炎效应。方法92例ACS患者随机分为三组:大剂量阿托伐他汀组31例,40 mg/d×30 d;标准剂量阿托伐他汀组31例,10 mg/d×30 d;对照组30例。结果(1)大剂量阿托伐他汀组在治疗后第5天和第30天CRP水平明显低于基础水平(P<0.05,P<0.001),而标准剂量阿托伐他汀组和对照组在第30天CRP水平明显降低(P均<0.05)。(2)与标准剂量阿托伐他汀组比较,大剂量阿托伐他汀组第5天和第30天的CRP水平降低更明显(P均<0.05)。(3)CRP水平与甘油三酯、低密度脂蛋白-胆固醇水平的变化无相关性。结论在ACS早期应用大剂量阿托伐他汀能迅速降低CRP水平,且这是一种独立于降脂作用之外的抗炎效应。
Objective To detemine that atorvastatin might have anti - inflammatory effects in acute coronary syndromes （ACS） with C-reactive protein （CRP） reduction. Methods Ninety-two patients with ACS were assigned to three groups： high dose atorvastatin group （31 cases）,taking atorvastatin 40mg daily. Standard dose atorvastatin group （31 cases）, taking atorvastatin 10mg daily, and control group （30 cases） ,only receiving conventional therapy. CRP levels, lipid profiles were measured at first and fifth day and 1 month later. Results The study suggested： （1）CRP levels significantly decreased from baseline to the fifth day and 1 month later in high dose atorvastatin group （P 〈 0.05 or 〈 0.001）respectively. Whereas, CRP level markedly reduced from baseline to 1 month late in standard dose atorvastatin group and control group（ P 〈 0.05）. （2） CRP levels were lower in high dose atorvastatin group versus standard dose atorvastatin group at fifth day and 1 month late （ P 〈 0.05）. （3） No correlation was found between changes in CRP and cholesterol levels in high dose atorvastatin group. Conclusions CRP levels in ACS are rapidly reduced with atorvastatin. The study provide evidence that atorvastatin hase faster and earlier anti - inflammatory effects in addition to lipid - lowing effects on ACS.
出处
《中国医师进修杂志（内科版）》
2006年第4期18-20,共3页
Chinese Journal of Postgraduates of Medicine
